Articles from Latigo Biotherapeutics, Inc

Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027

Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company’s pipeline of non-opioid pain treatment programs 

THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced that management will participate in the following investor conferences:

Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029

THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Latigo. The gross proceeds to Latigo from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Latigo, are expected to be $345.6 million. In addition, the underwriters have a 30-day option to purchase up to an additional 2,880,000 shares of common stock at the public offering price, less underwriting discounts and commissions.